To confirm significantly sex-based difference in the linearity of the association between TMB and patients outcome, we further analyzed data from 391 patients (128 women and 263 men), with EGFR and ALK wild-type advanced-NSCLC treated with the anti-PDL1 atezolizumab in the OAK and POPLAR RCTs.11 The gene discussed is ALK; the disease is non-small cell lung carcinoma.